Vestronidase Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy) and G-BA (Germany) recommended or restricted vestronidase alfa, while CIPM (Spain) and HAS (France) did not recommend it.
Assessment has run over 5 years, from 27 Feb 2019 at HAS (France) to 11 Feb 2024 at NYE METODER (Norway).
AIFA (Italy) changed its position: recommended on 7 Sep 2021, restricted by 7 Sep 2021.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for vestronidase alfa at all.
Against its own class, vestronidase alfa is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class A16A average 72%.
HAS (France) was first to assess vestronidase alfa, on 27 Feb 2019; NYE METODER (Norway) did not open a file until 11 Feb 2024 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed vestronidase alfa to a subgroup rather than accepting or refusing it outright, at AIFA (Italy) and G-BA (Germany).
2 of the 5 agencies here assessed vestronidase alfa more than once, AIFA (Italy) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed vestronidase alfa.
The full ledger for vestronidase alfa reads 3 not recommended, 2 restricted, 1 other and 1 recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 11 Feb 2024 | Behandling av ikke-nevrologiske manifestasjoner av mukopolysakkaridose VII (MPS VII; Slys sykdom). | decision recorded | source |
| AIFA (Italy) | 7 Sep 2021 | MEPSEVII e' indicato per la cura di manifestazioni non neurologiche di mucopolisaccaridosi VII (MPS VII; sindrome di Sly… | innovative, since expired | source |
| CIPM (Spain) | 15 Sep 2020 | Indicación terapéutica: Tratamiento de las manifestaciones no neurológicas de la mucopolisacaridosis VII (MPS VII; síndr… | not financed by the SNS · art. 92 d | source |
| HAS (France) | 24 Jun 2020 | Listing (Transparency Committee) | SMR insufficient | source |
| G-BA (Germany) | 22 Mar 2019 | Mepsevii — benefit assessment §35a | added benefit: non-quantifiable | source |
2 further decisions for vestronidase alfa, across 2 agencies, are not shown here.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 7 decisions for vestronidase alfa from 5 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.